HighLife raises $36m Series B for mitral valve replacement

HighLife said today that it raised a Series B round worth more than $36 million for the transcatheter mitral valve replacement it’s developing. HighLife’s TMVR uses a ring around the diseased valve’s leaflets that’s designed to guide the replacement valve into position. It’s designed to be delivered through the inter-atrial septum, rather than via a trans-apical approach involving a puncture in the heart muscle. The Paris-based company said proceeds from the $36.4 million (€32 million) Series B round are earmarked for completing regulatory approval trials aimed at winning CE Mark approval in Europe, and for an early feasibility trial in the U.S. HighLife raised a $14 million Series A round in October 2017. U.S. Venture Partners and Andera Partners led the Series B, with Sectoral Asset Management and chairman Jose Calle Gordo also participating. Sofinnova Partners, which led the Series A, also joined this round. “I am very pleased to announce the closing of the Series B financing round, which is essential to funding the development program of the company. The funds will support our mid-term strategy with a pivotal trial in Europe and a clinical trial in the U.S.,” founder & CEO Georg Börtlein said in prepared remarks. “We remain committed to bringing the best treatment option for the broadest patient population to market. Over the long term, we want to address any limitation that the field of TMVR faces and we will continue working towar...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured Funding Roundup Replacement Heart Valves Wall Street Beat HighLife Source Type: news